1) Profit margins should be better once a given drug is approved and sold 2) As with LFB, cheaper production means perhaps wider usage. When you can enter markets in which you can control price via lowered production costs you have increased control and lowered risk. 3) GTCB can attempt to produce drugs which have lower risk profiles for them because they have greater control. 4) The goal of GTCB researchers is not primarily searching for novel drugs like so many bio techs. It is primarily to match up opportunities with known capabilities.
Greater control equals lower risk is how I would sum it up in layman's terms.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.